



# Financial Tear Sheet


## Corporate Profile

G1 Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for the treatment of cancer. Two of the company's pipeline assets, trilaciclib and G1T38, are CDK4/6 inhibitors, a validated and promising class of oncology therapeutics. Trilaciclib and G1T38 have broad therapeutic potential in many forms of cancer and may serve as backbone therapy of multiple combination regimens. Trilaciclib is a short-acting IV CDK4/6 inhibitor designed to preserve hematopoietic stem cell and immune system function (myelopreservation) during chemotherapy. G1T38 is a potential best-in-class oral CDK4/6 inhibitor for use in combination with other targeted therapies. G1 is also advancing G1T48, a potential best-in-class oral selective estrogen receptor degrader, or SERD, which is targeted for the treatment of ER+ breast cancer. G1 owns or holds an exclusive license for worldwide commercial rights to each of its product candidates.

## Stock Performance

### GTHX (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$57.06</b>
Change (%)	<b>▲ 0.74 (1.31%)</b>
Volume	111,752
52 Week Low	\$12.57
Market Cap	\$1,881,343,411
Rolling EPS	-2.55
PE Ratio	0
Shares Outstanding	33,404,535



Data as of 08/14/18 4:00 p.m. ET

## Recent Headlines

08/08/18

G1 Therapeutics Provides Second Quarter 2018 Corporate and Financial Update

---

08/07/18

G1 Therapeutics to Present at Wedbush PacGrow Healthcare Conference on August 14, 2018

---

08/01/18

G1 Therapeutics to Provide Second Quarter 2018 Corporate and Financial Update on August 8, 2018

---

## Recent Events

<b>Date</b>	<b>Title</b>
08/14/18 9:10 a.m. ET	<b>2018 Wedbush PacGrow Healthcare Conference</b>

---

## SEC Filings

<b>Filing Date</b>	<b>Form</b>	<b>Description</b>
08/08/18	S-8	Securities offered to employees pursuant to employee benefit plans
08/08/18	10-Q	Quarterly report which provides a continuing view of a company's financial position
08/08/18	8-K	Report of unscheduled material events or corporate event
08/06/18	4	Statement of changes in beneficial ownership of securities

---

Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources